Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?

BACKGROUND: Urothelial carcinoma in situ (CIS) in the bladder can be difficult to diagnose due to factors including procedural artifact, minimal tissue sampled, therapy-related changes, and various CIS growth patterns. Prior data has demonstrated an increase in alpha-methylacyl-CoA-racemase (AMACR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Alston, Erin L. J., Zynger, Debra L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697956/
https://www.ncbi.nlm.nih.gov/pubmed/31419984
http://dx.doi.org/10.1186/s13000-019-0871-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697956/
https://www.ncbi.nlm.nih.gov/pubmed/31419984
http://dx.doi.org/10.1186/s13000-019-0871-8

Ejemplares similares